Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Blood (2017) 130 (Supplement 1): 340.

https://doi.org/10.1182/blood.V130.Suppl_1.340.340

Published: 2017

Journal Articles

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Rima M Panchal, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Nino Aleksidze, MD, Andrew L. Pecora, MD, Andre Goy, MD, Maribel Pereiras, Pharm D, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3283.

https://doi.org/10.1182/blood.V130.Suppl_1.3283.3283

Published: 2017

Journal Articles

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3284.

https://doi.org/10.1182/blood.V130.Suppl_1.3284.3284

Published: 2017

Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD

Blood (2017) 130 (Supplement 1): 5662.

https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662

Published: 2017

Journal Articles

Gene Expression Profiling (GEP) Is More Prognostic of OS and Post-ASCT PFS Compared to FISH in High-Risk Multiple Myeloma — a Single Center Experience

Miguel Gonzalez Velez, MD, Narjust Duma, MD, Badal Thakkar, MD MPH, Ning Dong, MD, Giselle Suero, MD PhD, David Siegel, MD PhD, Joshua R Richter, MD, David H. Vesole, MD PhD, Noa Biran, MD

Blood (2017) 130 (Supplement 1): 5369.

https://doi.org/10.1182/blood.V130.Suppl_1.5369.5369

Published: 2017

Journal Articles

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Blood (2017) 130 (Supplement 1): 1811.

https://doi.org/10.1182/blood.V130.Suppl_1.1811.1811

Published: 2017

Journal Articles

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

David Siegel, MD PhD, Gary J. Schiller, MD, Kevin W Song, MD, Richy Agajanian, Ketih Stockerl-Goldstein, Hakan Kaya, Michael Sebag, MD PhD, Christy Samaras, Ehsan Malek, MD, Giampaolo Talamo, Christopher S. Seet, Jorge Mouro, MS, Faiza Zafar, MPAS, Weiyuan Chung, Shankar Srinivasan, PhD, Max Qian, Amit Agarwal, MD PhD, Anjan Thakurta, PhD, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1812.

https://doi.org/10.1182/blood.V130.Suppl_1.1812.1812

Published: 2017

Journal Articles

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Dante Descalzi-Montoya, PhD, Kira Goldgirsh, MS, Zheng Yang, MS, Eugenia Dziopa, MS, Iriana Colorado, MS, Rena Feinman, PhD, Themba Nyirenda, PhD, David H. Vesole, MD, Pashna N. Munshi, MD, Scott D. Rowley, MD, Noa Biran, MD, Joshua R Richter, MD, David Siegel, MD PhD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2017) 130 (Supplement 1): 1862.

https://doi.org/10.1182/blood.V130.Suppl_1.1862.1862

Published: 2017

Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 2013.

https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013

Published: 2017

Journal Articles

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Blood (2017) 130 (Supplement 1): 1888.

https://doi.org/10.1182/blood.V130.Suppl_1.1888.1888

Published: 2017

Journal Articles

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Joshua R Richter, MD, Noa Biran, MD, Dhakshila Paramanathan, Srikesh Arunajadai, PhD, Victoria DeVincenzo, Ruth Pe Benito, Brooke Gruman, Sukhi Kaur, John Hervey, Eric Schultz, Scott Paddock, Andrew L. Pecora, MD, David H. Vesole, MD, David Siegel, MD PhD, Stuart L. Goldberg, MD

Blood (2017) 130 (Supplement 1): 679.

https://doi.org/10.1182/blood.V130.Suppl_1.679.679

Published: 2017

Journal Articles

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Yi Lin, MD PhD, Noopur Raje, MD, Nikhil Munshi, MD, David Siegel, MD PhD, Michaela Liedtke, MD, Sundar Jagannath, MD, Marcela V. Maus, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Kristen Hege, MD, Richard A. Morgan, PhD, Michael Travis Quigley, James N. Kochenderfer, MD

Blood (2017) 130 (Supplement 1): 740.

https://doi.org/10.1182/blood.V130.Suppl_1.740.740

Published: 2017

Journal Articles

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

A. Keith Stewart, MBChB, MBA, David Siegel, MD PhD, Heinz Ludwig, MD, Thierry Facon, MD, Hartmut Goldschmidt, MD, Andrzej J. Jakubowiak, MD, Jesus F. San Miguel, MD, Mihaela Obreja, Julie Blaedel, Meletios A. Dimopoulos

Blood (2017) 130 (Supplement 1): 743.

https://doi.org/10.1182/blood.V130.Suppl_1.743.743

Published: 2017

Journal Articles

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Blood (2017) 130 (Supplement 1): 395.

https://doi.org/10.1182/blood.V130.Suppl_1.395.395

Published: 2017

Journal Articles

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Nino Aleksidze, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4538.

https://doi.org/10.1182/blood.V130.Suppl_1.4538.4538

Published: 2017

Journal Articles

Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

Robert Korngold, PhD, Kira Goldgirsh, MS, Themba Nyirenda, PhD, Phyllis McKiernan, APN, MSN, Ryan Emerson, PhD, Marissa Vignali, PhD, Julie Rubinstein, Harlan Robins, PhD, David Siegel, MD PhD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4506.

https://doi.org/10.1182/blood.V130.Suppl_1.4506.4506

Published: 2017

Journal Articles

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

Miguel Gonzalez Velez, MD, Tracy Andrews, PhD, Narjust Duma, MD, Ning Dong, MD, Badal Thakkar, MD MPH, Giselle Suero, MD PhD, Joshua R Richter, MD, David H. Vesole, MD PhD, David Siegel, MD PhD, Noa Biran, MD

Blood (2017) 130 (Supplement 1): 3062.

https://doi.org/10.1182/blood.V130.Suppl_1.3062.3062

Published: 2017

Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD

Blood (2017) 130 (Supplement 1): 1831.

https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831

Published: 2017

Journal Articles

Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study

Meletios A. Dimopoulos, David Siegel, MD PhD, Darrell J. White, MD, Ralph V. Boccia, Zhao Yang, Amy S. Kimball, Karim Saad Iskander, Khalid Mezzi, MD MBA, Heinz Ludwig, MD, Ruben Niesvizky, MD

Blood (2017) 130 (Supplement 1): 1845.

https://doi.org/10.1182/blood.V130.Suppl_1.1845.1845

Published: 2017

Journal Articles

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

Katja C. Weisel, David Siegel, MD PhD, Jesus F. San Miguel, MD, Roman Hájek, MD, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Gianluca Gaidano, MD PhD, Robert Z. Orlowski, MD PhD, Lifen Zhou, Amy S. Kimball, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 1850.

https://doi.org/10.1182/blood.V130.Suppl_1.1850.1850

Published: 2017

NARROW

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Gene Expression Profiling (GEP) Is More Prognostic of OS and Post-ASCT PFS Compared to FISH in High-Risk Multiple Myeloma — a Single Center Experience

Safety and Efficacy of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) As Second- or Third-Line Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) after Lenalidomide (LEN)-Based Treatment (Tx) Failure

Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed

Early Regulatory and Memory T Cell Profiles Post-ASCT in the Presence of Checkpoint Inhibitor (Nivolimumab+Ipilimumab) Double Therapy in Patients with High-Risk Multiple Myeloma

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) + Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)

Incidence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients with Multiple Myeloma

Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial

Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

Gene Expression Profiling (GEP) As a Prognostic Indicator of Multiple Myeloma, Irrespective of Disease Stage, Prior Treatment and Prior Transplant - a Single Center Experience

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study

Overall Survival of Patients with Relapsed Multiple Myeloma Treated with Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone According to Prior Line of Therapy and Previous Exposure to Bortezomib: Secondary Analysis of the Phase 3 Endeavor Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only